Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2211-2216

  Singla, Smit ^a   Pippin, James A ^b   Drebin, Jeffrey A ^b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ErbB1; ErbB2; Lapatinib; Pancreas cancer

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; LAPATINIB; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOWN-REGULATION; DRUG SYNERGISM; FLUOROURACIL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84868135106     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2053     Document Type: Conference Paper

References (42)

1. Nelson NJ: Pancreatic cancer research matures. J Natl Cancer Inst 99:1432-1434, 2007.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 362:1605-1617, 2010.
3. Li J and Saif MW: Any progress in the management of advanced pancreatic cancer? JOP 10:361-365, 2009.
4. Zhu CP, Shi J, Chen YX, Xie WF and Lin Y: Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 99:108-113, 2011.
5. Heinemann V, Boeck S, Hinke A, Labianca R and Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82, 2008.
6. Yip D, Karapetis C, Strickland A, Steer CB and Goldstein D: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 3:CD002093, 2006.
7. Rivera F, Lopez-Tarruella S, Vega-Villegas ME and Salcedo M: Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 35:335-339, 2009.
8. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28:3605-3610, 2010.
9. Fountzilas G, Bobos M, Kalogera-Fountzila A, et al: Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest 26:784-793, 2008.
10. Moore MJ, Goldstein D, Hamm J, et al: National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007. (Pubitemid 46972777)
11. Safran H, Iannitti D, Ramanathan R, et al: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress ERBB2/neu. Cancer Invest 22:706-712, 2004. (Pubitemid 40064730)
12. Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565, 2000. (Pubitemid 32197693)
13. Riese DJ II and Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41-48, 1998. (Pubitemid 28111330)
14. Ueda S, Ogata S, Tsuda H, et al: The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29:e1-e8, 2004.
15. Dancer J, Takei H, Ro JY and Lowery-Nordberg M: Coexpression of ERBB1 and ERBB2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization. Oncol Rep 18:151-155, 2007.
16. Tobita K, Kijima H, Dowaki S, et al: Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 11:305-309, 2003.
17. Scaltriti M, Rojo F, Ocana A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638, 2007. (Pubitemid 47073544)
18. Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639, 2006. (Pubitemid 43259947)
19. O'Brien NA, Browne BC, Chow L, et al: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:1489-1502, 2010.
20. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011.
21. Mehta SP: Palliative chemotherapy for pancreatic malignancies. Surg Clin North Am 90:365-375, 2010.
22. Muthuswamy SK, Gilman M and Brugge JS: Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo-and heterodimers. Mol Cell Biol 19:6845-6857, 1999. (Pubitemid 29441868)
23. Zwick E, Hackel PO, Prenzel N and Ullrich A: The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 20:408-412, 1999. (Pubitemid 29450362)
24. Sorkin A, Helin K, Waters CM, Carpenter G and Beguinot L: Multiple autophosphorylation sites of the epidermal growth factor receptor are essential for receptor kinase activity and internalization. Contrasting significance of tyrosine 992 in the native and truncated receptors. J Biol Chem 267:8672-8678, 1992.
25. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-584, 1998. (Pubitemid 28563719)
26. Liu BB and Wang WH: Survivin and pancreatic cancer. World J Clin Oncol 2:164-168, 2011.
27. Theodoropoulos GE, Michalopoulos N V, Panoussopoulos SG, Taka S and Gazouli M: Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 39:976-980, 2010.
28. Shen YM, Yang XC, Song ML, Qin CH, Yang C and Sun YH: Growth inhibition induced by short hairpin RNA to silence survivin gene in human pancreatic cancer cells. Hepatobiliary Pancreat Dis Int 9:69-77, 2010.
29. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007. (Pubitemid 46799492)
30. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J and Jovin TM: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473-482, 2005.
31. Xia W, Liu LH, Ho P and Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23:646-653, 2004. (Pubitemid 38241266)
32. Xia W, Mullin RJ, Keith BR, et al: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263, 2002.
33. Song Z, Yao X and Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278:23130-23140, 2003. (Pubitemid 36830379)
34. Wang Z, Fukuda S and Pelus LM: Survivin regulates the p53 tumor suppressor gene family. Oncogene 23:8146-8153, 2004. (Pubitemid 39531855)
35. Desplanques G, Hulin P, Juin P and Barille-Nion S: Survivin Protects Breast Cancer Cells from DNA Damage during Mitosis (abstract). In: Thirty-Second Annual CTRC-AACR San Antonio Breast Cancer Symposium, Dec. 10-13; San Antonio, TX, 2009.
36. Cancer Res 69(Suppl 3), 2009.
37. Boussen H, Cristofanilli M, Zaks T, De Silvio M, Salazar V and Spector N: Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 28:3248-3255, 2010.
38. Lo Russo PM, Jones SF, Koch KM, et al: Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 26:3051-3056, 2008.
39. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008.
40. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009.
41. Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al: Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 13:4495-4502, 2007. (Pubitemid 47219719)
42. Midgley RS, Kerr DJ, Flaherty KT, et al: A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 18:2025-2029, 2007. (Pubitemid 350286244)